Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview

Clarke, Mike

doi:10.1093/annonc/mdl238

Cited by 89 publications

(56 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the incidence of breast cancer continues to rise, mortality has declined over the past several years (1,2). The decline has been attributed to both early diagnosis and more effective treatment (2).…”

mentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Lee¹,

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article, part 1 in a 2-part series, provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provides an overview of clinical and biologic considerations in breast cancer and covers radionuclide imaging for detection and staging. Part 2 will cover radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.

show abstract

mentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Lee¹,

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…In addition to their indisputable numerous roles in the physiology of healthy organisms, a growing body of work indicates they also represent an important pharmaceutical target in number of diseases including cancer. For instance, ER and PR are important targets in the breast cancer [2,3], while AR is the major therapeutic target in prostate tumors [4]. Ligands antagonizing natural hormone ligands for these receptors with reduced side effects are intensively sought as potential drugs for cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling

Sedlak¹,

Paguio²,

Bartůněk³

2011

CCHTS

View full text Add to dashboard Cite

Steroid hormone receptors represent a major target in drug discovery. As ligand inducible transcription factors, their activity can be modulated by small lipophilic molecules. Here we describe two panels of potent and selective luciferase reporter cell lines based on cells with low endogenous steroid receptor activity (U2OS). The panels contain reporter cell lines for estrogen receptors and , androgen, glucocorticoid, mineralocorticoid, and progesterone receptors. In the first panel, the activation of either synthetic, steroid response elements containing promoter or viral promoter is mediated by full-length steroid receptors. The second panel is based on the expression of the chimeric receptor, which was created by the replacement of the N-terminal part of the molecule by Gal4 DBD and that binds to multiple UAS sites in the reporter promoter. Both panels were extensively characterized by profiling 28 ligands in dose response manner in agonist and antagonist mode. We have analyzed and compared the responses to tested ligands from both panels and concluded that in general both systems generated similar qualitative response in terms of potency, efficacy, partial agonism/antagonism, mixed agonistic/antagonistic profiles and the rank of potencies was well conserved between both panels. However, we have also identified some artifacts introduced by the Gal4/LBD reporter assays in contrast to their full-length receptor reporter counterparts. Keeping in mind the advantages and drawbacks of each reporter format, these cell lines represent powerful and selective tools for profiling large compound libraries (HTS) and for detailed study of mechanisms by which compounds exert their biological effects.

show abstract

“…However, many breast tumors eventually develop resistance to cytotoxic chemotherapeutic agents, and tumors can recur even with the use of adjuvant therapies. [2][3][4][5][6][7][8] Ipsilateral breast tumors may recur after resection and/or radiation therapy even with adjuvant therapies. 5,9,10 When combined with surgery, therapies that target specific unregulated cell proliferation and angiogenic signaling pathways have often demonstrated improved outcomes, oftentimes with less severe side effects.…”

Section: Introductionmentioning

confidence: 99%

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Suchy¹,

Hancher²,

Wang³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview

Cited by 89 publications

References 12 publications

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Contact Info

Product

Resources

About